Cargando…

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study

OBJECTIVE: Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study. DESIGN: Double-blind, randomised, non-inferiority study; single-blind extension stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawai, Takashi, Oda, Kazunori, Funao, Nobuo, Nishimura, Akira, Matsumoto, Yasushi, Mizokami, Yuji, Ashida, Kiyoshi, Sugano, Kentaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Gastroduodenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969345/ https://www.ncbi.nlm.nih.gov/pubmed/29196436 http://dx.doi.org/10.1136/gutjnl-2017-314852

Ejemplares similares

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
por: Mingrone, Geltrude, et al.
Publicado: (2022)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2011)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2016)

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
por: Iwakiri, Katsuhiko, et al.
Publicado: (2017)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
por: Xiao, Yinglian, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2019)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials
por: Miwa, H., et al.
Publicado: (2016)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2012)

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
por: Sakurai, Yuuichi, et al.
Publicado: (2016)

Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study
por: Ban, Hiromitsu, et al.
Publicado: (2021)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

Gastroduodenal Intussusception Due to Vonoprazan-induced Gastric Polyps
por: Nishimura, Naoyuki, et al.
Publicado: (2021)

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
por: Marabotto, Elisa, et al.
Publicado: (2020)

Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data
por: Moraes-Filho, Joaquim Prado P., et al.
Publicado: (2022)

Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial
por: Kawai, Daisuke, et al.
Publicado: (2021)

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
por: Chinzon, Décio, et al.
Publicado: (2021)

Gastroduodenal ulcer bleeding in elderly patients on low dose aspirin therapy
por: Fukushi, Koh, et al.
Publicado: (2018)

Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
por: Tabuchi, Maiko, et al.
Publicado: (2021)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
por: Suzuki, Yoshiharu, et al.
Publicado: (2021)

Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial
por: Tilbrook, Helen, et al.
Publicado: (2015)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan‐associated long QT syndrome
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers
por: Takahashi, Kazuya, et al.
Publicado: (2016)

Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection
por: Hojo, Mariko, et al.
Publicado: (2020)

Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study
por: Uchiyama, Shinichiro, et al.
Publicado: (2019)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3uhl69nghtghhij49h8or0hk7